| Literature DB >> 22505920 |
Abstract
An efficient and environmentally friendly sample preparation method based on the application of hydrophobic 1-Hexylpyridinium hexafluorophosphate [Hpy][PF(6)] ionic liquid (IL) as a microextraction solvent was proposed to preconcentrate terazosin. The performance of the microextraction method was improved by introducing a common ion of pyridinium IL into the sample solution. Due to the presence of the common ion, the solubility of IL significantly decreased. As a result, the phase separation successfully occurred even at high ionic strength, and the volume of the settled IL-phase was not influenced by variations in the ionic strength (up to 30% w/v). After preconcentration step, the enriched phase was introduced to the spectrofluorimeter for the determination of terazosin. The obtained results revealed that this system did not suffer from the limitations of that in conventional ionic-liquid microextraction. Under optimum experimental conditions, the proposed method provided a limit of detection (LOD) of 0.027 μg L(-1) and a relative standard deviation (R.S.D.) of 2.4%. The present method was successfully applied to terazosin determination in actual pharmaceutical formulations and biological samples. Considering the large variety of ionic liquids, the proposed microextraction method earns many merits, and will present a wide application in the future.Entities:
Year: 2012 PMID: 22505920 PMCID: PMC3296212 DOI: 10.1155/2012/546282
Source DB: PubMed Journal: Int J Anal Chem ISSN: 1687-8760 Impact factor: 1.885
Figure 1(a) Emission spectra obtained for 8 standard solutions of terazosin with different concentrations. (b) Emission spectrum of terazosin (75 μg L−1) treated the same as previously described in the general analytical procedure (a), and emission spectrum of reagent blank in [Hpy][PF6] ionic liquid (b). Inset: chemical structure of [Hpy][PF6] ionic liquid. Experimental conditions were as indicated in the Table 1.
Figure 2Influence of amount of [Hpy][PF6] on the fluorescence intensities. Experimental conditions: terazosin concentration 75 μg L−1; pH 10; NaPF6 350 mg.
Figure 3Influence of NaPF6 on the analytical signals obtained for terazosin. Experimental conditions: terazosin concentration 75 μg L−1; pH 10; [Hpy][PF6] 150 mg.
Figure 4Influence of pH on the fluorescence intensities. Experimental conditions: terazosin concentration 75 μg L−1; [Hpy][PF6] 150 mg; NaPF6 350 mg. Inset: chemical structure of terazosin. Acid base equilibrium involved at working pH. (a) Protonated form of this terazosin; (b) dissociated form of terazosin.
The experimental conditions for terazosin determination.
| Microextraction parameters | Studied range | Selected condition |
|---|---|---|
| Amount of NaPF6 (mg) | 0–400 | 350 |
| Amount of [Hpy][BF4] (mg) | 25–400 | 150 |
| pH | 5–12 | 10 |
| Equilibration temperature (°C) | 5–40 | Room temperature |
| Centrifugation time (min) | 1–15 | 5 |
| Ionic strength (% w/v) | 0–40 | NEa |
|
| ||
| Instrumental parameters | ||
| Excitation wavelength (nm) | 200–350 | 330 |
| Emission wavelength (nm) | 350–700 | 376 |
| Excitation and emission slit widths (nm) | 5–20 | 10 |
aNo effect.
Determination of terazosin in tablets by the proposed methodology and by a reported voltammetric method [8].
| Claimed (mg/tablet) | Proposed methodology (mg)a | Reported method (mg)a | Error (%)b | Error (%)c |
|---|---|---|---|---|
| 2 | 1.95 (±0.08) | 2.07 (±0.10) | −2.5 | −5.8 |
| 5 | 5.1 (±0.21) | 5.27 (±0.37) | +2.0 | −3.2 |
aValues in parenthesis show the standard deviation based on three replicates.
bError against the declared value.
cError against the reported method.
Determination of terazosin in spiked urine and spiked plasma by present work.
| Drug | Spiked urine | Spiked plasma | ||||
|---|---|---|---|---|---|---|
| Amount added ( | Amount found ( | Recovery (%) | Amount added ( | Amount found ( | Recovery (%) | |
| Terazosin | 2 | 1.83 ± 0.09 | 91.5 | 2 | 1.73 ± 0.11 | 86.5 |
| 5 | 4.81 ± 0.28 | 96.2 | 5 | 4.82 ± 0.33 | 96.4 | |
| 10 | 9.40 ± 0.30 | 94.0 | 10 | 9.60 ± 0.51 | 96.0 | |
| 100 | 105.81 ± 4.11 | 105.8 | 100 | 93.10 ± 4.88 | 93.1 |
aAverage of three independent measurements.
Comparison of the proposed approach with other reported methods for determination of terazosin.
| Method | Sample | LOD ( | R.S.D. (%) | LR ( | References |
|---|---|---|---|---|---|
| Spectrofluorimetry | Serum, urine | 210 | 2.5 | Up to 3486.9 | [ |
| X-ray fluorescence spectrometry | Drug | 732 | — | 732–843000 | [ |
| HPLC with fluorescence detection | Plasma | 0.25 | <7 | Up to 100 | [ |
| HPLC with electrospray ionization mass spectrometry detection | Plasma | 0.0625 | — | — | [ |
| Square-wave adsorptive cathodic stripping voltammetry | Plasma, drug | 0.0058 | <1.1 | 0.39–11.62 | [ |
| ionic-liquid microextraction spectrofluorimetry | Urine, plasma, drug | 0.027 | 2.4 | 0.1–115 | This work |
LOD: limit of detection, LR: linear range, R.S.D.: relative standard deviation.